Obstructive Sleep Apnea
Also known as: Obstructive Sleep Apnoea Syndrome (OSAS) / Obstructive Sleep Apnoea / Sleep Apnea Syndromes, Obstructive / Obstructive Sleep Apnea (OSAS) / OSA / Apnea, Obstructive Sleep / Sleep Apnea Syndrome (OSAS) / Obstructive Sleep Apnoea (OSA) / Sleep Apnea, Obstructive / Sleep Apnea, Obstructives / Obstrutive Sleep Apnea / Obstructive Sleep-Apnea Syndrome / Obstructive Sleep Apnoea Syndrome / OSAS / Obstructive Sleep Apnea (SAOS) / Sleep Apnea Syndrome, Obstructive / Obstructive Sleep Apnea Syndrome / Obstructive Sleep Apnea Syndrome and / Sleep Apnea - Obstructive / Obstructive Sleep Apnea Syndrome (OSAS) / OSA - Obstructive Sleep Apnea / Obstructive Sleep Apnea Syndromes / OSAS (Obstructive Sleep Apneas Syndrome) / Sleep Obstructive Apnea / Sleep Apnea Obstructive (OSA) / Obstructive Sleep Apnea (OSA) / Syndrome, Obstructive Sleep Apnea / Obstructive sleep apnea (adult) (pediatric) / Sleep apnoea-hypopnoea syndrome / Sleep apnea-hypopnea syndrome / Obstructive sleep apnea syndrome (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00745 | Modafinil | A stimulant used to improve wakefulness in patients with sleep apnea, narcolepsy, or shift work disorder. |
| DB14754 | Solriamfetol | Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients[FDA Label][A176534,A176744]. |